In the past year, advances in genome editing with CRISPR and immunotherapy have accelerated the pace of discovery of novel constructs to win the war against cancer. The armamentarium of tools has resulted in rapid progress in the advancement of new therapies to the clinic, but a major bottleneck remains the discovery and validation of novel targets. The Novel Targets for Cancer and Emerging Therapeutic Areas conference at PEGS Europe will look at innovative approaches to uncover and vet novel targets that can lead to first-in-class medicines in oncology and beyond.

Preliminary Agenda

DISCOVERING DISEASE-ASSOCIATED EPITOPES AND PATIENT-DERIVED APPROACHES

Using Phage Display of Antibodies as a Discovery Tool to Identify Disease-Related Targets

Peter Kristensen, PhD, Head of Section of Biotechnology, Associate Professor, Department of Chemistry and Bioscience, Aalborg University

Microsphere Affinity Proteomics: High Throughput Deconvolution of Antibody Libraries

Fridtjof Lund-Johansen, MD, PhD, Senior Scientist, Department of Immunology, Oslo University Hospital

Targeting Early Changes in the Synovial Microenvironment: A New Class of Immunomodulatory Therapy?

Kim Midwood, Professor at Kennedy Institute of Rheumatology, University of Oxford

B CELL-DERIVED ANTIBODIES FROM TUMOURS

BCR-Dependent Lineage Plasticity in Mature B Cells

Robin Graf, Dr. rer. nat., Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Targeting LILRB4 for Cancer Therapy

Zhiqiang An, PhD, Professor and Robert A. Welch Distinguished University Chair, Chemistry, Brown Foundation Institute of Molecular Medicine, Director, Texas Therapeutics Institute, University of Texas Health Science Center, Houston

DOMINANT TARGETS

Antibody Discovery for Metabolic Enzyme and Immuno-Oncology Targets

Maria Groves, PhD, Associate Director, Lab Head for the CRUK/Medimmune Alliance, AstraZeneca

CHALLENGES AHEAD FOR CANCER IMMUNOTHERAPY/IMMUNE PHENOTYPES

A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions

Daniel Chen, MD, PhD, CMO, IGM Biosciences

Avidity-Based Binding to HER2 Results in Selective Killing of HER2 Over-Expressing Cells by Anti-HER2/CD3

Teemu Juntilla, PhD, Senior Scientist, Translational Oncology, Genentech

NEXT GENERATION APPROACHES (ANTIBODY-BASED)

Engineered IgM-Based Antibodies

Bruce Keyt, PhD, CSO, IGM Biosciences

Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors

Kanako Tatsumi, PhD, Researcher, Discovery Biologics, Chugai Pharmaceutical Co., Ltd.



* The program is subject to change without notice, due to unforeseen reason.


Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean